SAN DIEGO, Sept. 15 Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
Certain of the statements within this shareholder letter may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the Company's ability to forge corporate partnerships on terms acceptable to the Company or at all, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Advertisement
To our Shareholders: In advance of tomorrow's annual meeting, I wish to thank those shareholders who returned proxies supporting measures to re-elect our board of directors, reappoint our auditors, and increase the authorized shares of our common stock. The results of your votes will be tabulated during our meeting and disclosed shortly thereafter. I would also like to take this opportunity to disclose that our manufacturing program with Bioserv/NextPharma Technologies is now underway, and that infectious disease researchers have provided initial verification that our Hemopurifier(R) is able to capture the emerging H1N1 swine flu virus. We are additionally honored to reestablish a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that will continue our research into treating Ebola and other highly lethal pathogens. While I am pleased we have advanced these initiatives, our primary focus remains directed towards leveraging our therapeutic opportunity in Hepatitis-C care and establishing strategic relationships that will maximize long-term economic value for shareholders. In this regard, we are actively pursuing relationships that offer to augment or significantly expand our clinical, distribution, and manufacturing capabilities. However, I want to stress the complexity underlying any such relationship should not be underestimated. We face issues that include competition between players in the medical device space, scaling of manufacturing at feasible costs, and developing appropriate distribution channels in a variety of markets. Additionally, we maintain a firm stance that Aethlon Medical shareholders should maintain 100% ownership of our Hemopurifier(R) technology. Regardless of these challenges, I am increasingly confident that we will establish relationships that provide us the foundation to transition our science into a successful business enterprise. On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support and look forward to meeting those of you who attend tomorrow's meeting. Very truly yours, James A. Joyce Chairman, CEO
SOURCE Aethlon Medical, Inc.
